Biological barriers to drug/gene delivery prevent successful accumulation of nanotherapeutics specifically at diseased sites,limiting efficacious responses in disease processes.Site-specific delivery of therapeutics will remain a distant reality unless carrier design takes into account the majority,if not all,of the biological barriers.